Publication Topic

nonclinical safety assessment (4 POSTS)

2019 (1 POST)

Bussiere JL, Davies R, Dean C, Xu C, Kim KH, Vargas HM, Chellman GJ, Balasubramanian G, Monticello TM. 2019. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol 106(Aug):224-238; doi: 10.1016/j.yrtph.2019.05.013.

View Abstract

2018 (1 POST)

Monticello TM, Bussiere JL. 2018. Nonclinical safety evaluation of drugs. Chapter 2 in: Sahota PS, Popp JA, Hardisty JF, Gopinath C. (eds), Toxicologic Pathology: Nonclinical Safety Assessment, 2nd edition. Boca Raton: CRC Press.

2017 (1 POST)

Monticello TM, Jones TW, Dambach DM, Potter DM, Bolt MW, Liu M, Keller DA, Hart TK, et al. 2017. Current nonclinical testing paradigm enables safe entry to First-in-Human clinical trials: The IQ consortium nonclinical translational database. Toxicol Appl Pharmacol 334(Nov 1):100-109; doi: 10.1016/j.taap.2017.09.006.

View Abstract

2012 (1 POST)

Monticello TM, Bussiere JL. 2012. Nonclinical safety evaluation of drugs. Chapter 2 in: Sahota PS, Popp JA, Hardisty JF, Gopinath C. (eds), Toxicologic Pathology: Nonclinical Safety Assessment. Boca Raton: CRC Press, pp. 25-54.